期刊
CANCERS
卷 13, 期 20, 页码 -出版社
MDPI
DOI: 10.3390/cancers13205174
关键词
natural killer T cells; iNKT cells; type II NKT cells; cancer; immunotherapy; alpha-galactosylceramide; CAR-NKT cells; adoptive transfers; checkpoint inhibitors; cancer vaccines
类别
资金
- CIHR [PJT-153285]
- Terry Fox Research Institute
- CIBC
- Dalhousie Medical Research Foundation
- Craig's Cause Pancreatic Society
NKT cells are a specialized subset of lipid-reactive T lymphocytes that play direct and indirect roles in immunosurveillance and anti-tumor immunity. Preclinical studies have shown that NKT cell activation via delivery of exogenous glycolipids elicits a significant anti-tumor immune response. This review also examines challenges and future directions for improving the therapy.
Simple Summary Natural killer T (NKT) cells are a subset of lipid-reactive T cells that enhance anti-tumor immunity. While preclinical studies have shown NKT cell immunotherapy to be safe and effective, clinical studies lack predictable therapeutic efficacy and no approved treatments exist. In this review, we outline the current strategies, challenges, and outlook for NKT cell immunotherapy. NKT cells are a specialized subset of lipid-reactive T lymphocytes that play direct and indirect roles in immunosurveillance and anti-tumor immunity. Preclinical studies have shown that NKT cell activation via delivery of exogenous glycolipids elicits a significant anti-tumor immune response. Furthermore, infiltration of NKT cells is associated with a good prognosis in several cancers. In this review, we aim to summarize the role of NKT cells in cancer as well as the current strategies and status of NKT cell immunotherapy. This review also examines challenges and future directions for improving the therapy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据